Clinical Trials Logo
  1. Home
  2. High Grade Serous Carcinoma
  3. NCT03462342

Combination ATR and PARP Inhibitor (CAPRI) Trial With AZD6738 and Olaparib in Recurrent Ovarian Cancer — CAPRI  

High Grade Serous Carcinoma Clinical Trial

Official title:
Combination ATR and PARP Inhibitor (CAPRI) Trial With AZD 6738 and Olaparib in Recurrent Ovarian Cancer

Clinical Trial Summary

Investigational agent, AZD6738 will be given in combination with Olaparib to women with recurrent ovarian cancer (platinum-sensitive or platinum-resistant). This study will determine if using Olaparib in combination with AZD6738 is safe and tolerable and also determine the objective response rate and progression free survival of combination of AZD6738 and Olaparib in women with recurrent ovarian cancer in distinct platinum-sensitive and platinum-resistant cohorts.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT03462342
Study type Interventional
Source University of Pennsylvania
Contact Diego Rodriguez
Phone 215-220-9519
Email PerelmanGyn/OncResearchCoordinatorPool@uphs.upenn.edu
Status Recruiting
Phase Phase 2
Start date March 9, 2018
Completion date December 31, 2024
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT05537844 - Longitudinal Sample Collection to Investigate Adaptation and Evolution of Ovarian High-grade Serous Carcinoma
Recruiting NCT05358639 - Combination of Olaparib and Navitoclax in Women With HGSC and TNBC Phase 1
Recruiting NCT03738319 - Non-coding RNA in the Exosome of the Epithelia Ovarian Cancer
Recruiting NCT05080556 - Adaptive ChemoTherapy for Ovarian Cancer in Patients With Replased Platinum-sensitive High Grade Serous or High Grade Endometrioid Ovarian Cancer Phase 2
Recruiting NCT03509246 - Bortezomib and Pegylated Liposomal Doxorubicin in BRCA Wild-type Platinum-resistant Recurrent Ovarian Cancer Patients Phase 2
Withdrawn NCT05390021 - PET/MRI in Endometrial Cancer N/A
Terminated NCT04598321 - BrUOG 390: Neoadjuvant Treatment With Talazoparib Phase 1
Completed NCT05490407 - Role of the ATP7A Transporter in Ovarian Cancer N/A
Recruiting NCT04846933 - Multi-layer Data to Improve Diagnosis, Predict Therapy Resistance and Suggest Targeted Therapies in HGSOC
Completed NCT03593681 - Compare Fallopian Tube Cells Collected by Cytuity With Removed Ovarian/Tubal Tissue to Determine Presence of Malignancy
Terminated NCT03824704 - A Study to Evaluate Rucaparib in Combination With Nivolumab in Patients With Selected Solid Tumors (ARIES) Phase 2